Steve Jobs – Medical science failed to save a computer novel

3

Steven Paul Jobs, 56, died Wednesday at his home with his family. The co-founder and, until last August, CEO of Apple Inc was the most celebrated person in technology and business on the planet. No one will take issue with the official Apple statement that “The world is immeasurably better because of Steve.”

It was known that Mr. Jobs suffered from pancreatic cancer more than seven years ago and recently had a liver transplant. He was treated for an islet cell neuroendocrine tumor, a slow moving and relatively treatable form of pancreatic cancer, which is more often associated with a faster spreading much more aggressive pancreatic tumor. He also underwent the liver transplant about 2 years ago.

Medical Experts not involved with Mr. Jobs care, speculated that cancer was most likely the cause of his death although complications from the liver transplant, the transplanted organ ceasing to function or problems with the immune-suppressing medicines (to prevent organ rejection) might also have been involved.

Many doctors speculated he had a Whipple procedure, in which part of the pancreas, part of the small intestine and in some cases part of the stomach are removed and the digestive system is reconstructed.

Jobs said little about pancreatic cancer struggle
The Apple founder long kept information on his illness behind a firewall and no body new details, which emerged immediately after his death.

However, medical experts say Jobs most likely needed the transplant because his cancer came back or spread. They said his death could have been from cancer, the new liver not working, or complications from immune-suppressing medicines to prevent organ rejection.

A liver transplant can cure Jobs’ type of cancer, but “if it were to come back, it’s usually in one to two years,” said Dr. Michael Pishvaian, cancer specialist at Georgetown University’s Lombardi Comprehensive Cancer centre.

The Apple chief never revealed whether the cancer had spread to his lymph nodes...



or liver, or how extensive his surgery was. Many doctors speculated he had a Whipple procedure, in which part of the pancreas, part of the small intestine and in some cases part of the stomach are removed and the digestive system is reconstructed.

Several years later, Jobs was dramatically thinner and gaunt. In January 2009, he attributed those problems to a hormone imbalance and said there was a simple treatment for it. A few weeks later, he went on a medical leave and then had a liver transplant that was kept secret for two months.

Even then, Jobs would not say why the transplant was needed, though doctors said spread of his cancer to the liver was the likely explanation. Usually transplants aren’t done for people with cancer, but “there is some support for the idea that a liver transplant can be curative” for a neuroendocrine tumor as long as the cancer has not spread beyond the liver, Pishvaian said.

Average survival for people with neuroendocrine tumors that have spread is seven to eight years, and some patients have survived 20 to 30 years, said Dr. Martin Heslin, cancer surgery chief at the University of Alabama at Birmingham.

Goodbye Steve Jobs ~ Another 20+ years would have served you and most of the world much better.  Last but not the least, I liked the statement by Obama “Steve was among the greatest of American innovators — brave enough to think differently, bold enough to believe he could change the world and talented enough to do it.”

Via

3 Responses

  1. jasmine says:

    THANK YOU STEVE JOBS . IF IT WASN’T FOR YOU THE WORLD WILL NOT BE WITH TECHNOLOGY.AND IT WILL BE BORING…..

    —–JASMINE <3——— THANK YOU STEVE JOBS!!!!!!!

  2. Bob Thomson says:

    The loss of Steve Jobs is very sad as he was a true giant in the tech field. I often wondered if Jobs knew about, or was offered Low Dose Naltrexone/ALA treatment such as that that Dr Burt Berkson has had such success with with pancreatic cancer patients in New Mexico.
    I had the pleasure of hearing about this from him first hand at the first EU Low Dose Naltrexone conference in 2009 –
    http://glasgowldn2009.com/category/conference-sessions/

    Whether you consider LDN a controversial treatment or not, you have to admit that given the stats here, anything should be offered as an option surely?

    Read more: http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2011/10/07/national/a145842D53.DTL#ixzz1aBNsXoEF

Leave a Reply

 
© 2012 Healthy Living. All rights reserved.
Proudly designed by Theme Junkie.